MARKET

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.550
-0.070
-4.32%
Closed 16:00 11/11 EST
OPEN
1.600
PREV CLOSE
1.620
HIGH
1.640
LOW
1.450
VOLUME
75.12K
TURNOVER
--
52 WEEK HIGH
16.60
52 WEEK LOW
1.450
MARKET CAP
37.32M
P/E (TTM)
-0.2214
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EARS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EARS News

  • Do Institutions Own Auris Medical Holding Ltd. (NASDAQ:EARS) Shares?
  • Simply Wall St..16h ago
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings
  • Benzinga.10/30 11:01
  • The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug
  • Benzinga.10/22 11:51

More

Industry

Biotechnology & Medical Research
-0.40%
Pharmaceuticals & Medical Research
-0.41%

Hot Stocks

Name
Price
%Change

About EARS

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
More

Webull offers Auris Medical Holding Ltd (EARS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.